{"product_id":"kobayashi-five-forces-analysis","title":"Kobayashi Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eKobayashi’s Porter’s Five Forces snapshot highlights supplier leverage, buyer sensitivity, rivalry intensity, substitute threats, and entry barriers shaping its competitive landscape—useful for quick orientation and risk spotting.\u003c\/p\u003e\n\u003cp\u003eThis brief preview only scratches the surface; unlock the full Porter’s Five Forces Analysis to get force-by-force ratings, visuals, and actionable strategy tailored to Kobayashi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Commodity Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKobayashi depends on chemical and natural commodities—over 40% of COGS in FY2024 were raw materials—so global price swings (e.g., 2022–24 average volatility: ~18% annually for key petrochemicals) can compress margins if suppliers pass costs on. Kobayashi keeps multiple suppliers and 3 regional procurement hubs to limit single‑source risk; maintaining 6–12 months safety stock cut production stoppages by 35% in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Ingredient Dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain niche products need biological or chemical extracts from about 6 certified global vendors, concentrating supply and giving those suppliers price leverage; suppliers raised prices 7–12% in 2025 vs 2023 for specialty extracts. \u003c\/p\u003e\n\u003cp\u003eAfter 2024 recalls, safety audits doubled and only ~40% of previous vendors passed new compliance, shrinking the qualified pool and strengthening suppliers’ contract terms and minimum order requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Compliance and Safety Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Kobayashi enforced stricter upstream quality controls, raising suppliers’ compliance and safety costs by an estimated 8–12% per supplier; suppliers report capital outlays of $150k–$1.2M for testing and certification. These higher costs give capable, certified suppliers pricing leverage, enabling price increases of 3–7% without losing contracts. As regulators increase inspections, supplier bargaining power shifts toward those guaranteeing purity and safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Specialized Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanging suppliers for active pharmaceutical ingredients (APIs) carries heavy regulatory hurdles—FDA or PMDA revalidation can take 6–18 months and cost $0.5–$5M per SKU—so Kobayashi faces high switching costs that deter moves to cheaper sources.\u003c\/p\u003e\n\u003cp\u003eThose costs risk production delays and lost revenue (example: a 3‑month shutdown on a $20M drug line wipes ~$5M gross profit), keeping established API suppliers influential in the value chain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory revalidation: 6–18 months\u003c\/li\u003e\n\u003cli\u003eRequalification cost per SKU: $0.5–$5M\u003c\/li\u003e\n\u003cli\u003e3‑month shutdown impact: ~$5M gross profit on $20M annual line\u003c\/li\u003e\n\u003cli\u003eResult: suppliers retain pricing and supply leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForward Integration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwhile most raw-material suppliers lack kobayashi consumer-branding skill large chemical conglomerates like mitsui chemicals and sumitomo revenue\u003e¥1.2tn each) are launching finished goods lines, raising forward-integration risk to procurement and margins.\n\u003cphowever kobayashi specialized consumer-health branding market share in japan estimate and direct retail channels create a strong moat that keeps this threat limited.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge suppliers entering finished goods (2024–25 moves)\u003c\/li\u003e\n\u003cli\u003eRisk: procurement leverage, margin pressure\u003c\/li\u003e\n\u003cli\u003eDefence: 12% domestic share, branded R\u0026amp;D, retail footprint\u003c\/li\u003e\n\u003cli\u003eAction: lock long-term contracts, co-branding, SKU exclusivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phowever\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers exert moderate‑high pricing power; raw materials 40%+ and costly API switches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate‑high power: raw materials = 40%+ COGS (FY2024), petrochemical volatility ~18% pa (2022–24), niche extracts from 6 vendors saw price hikes 7–12% (2023–25), API switch costs 6–18 months and $0.5–$5M per SKU, safety compliance raised supplier costs 8–12% and allowed 3–7% price increases, but Kobayashi’s 12% Japan share limits full forward‑integration risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials (%COGS)\u003c\/td\u003e\n\u003ctd\u003e40%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePetrochem volatility\u003c\/td\u003e\n\u003ctd\u003e~18% pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche price rise\u003c\/td\u003e\n\u003ctd\u003e7–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI revalidation\u003c\/td\u003e\n\u003ctd\u003e6–18 months; $0.5–$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier cost raise\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand share (Japan)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Five Forces analysis for Kobayashi that uncovers competitive intensity, supplier and buyer power, threat of substitutes and new entrants, and identifies disruptive forces and strategic levers to protect profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eKobayashi Porter's Five Forces in one sheet—instantly reveal competitive pressure hotspots and relieve strategic uncertainty for faster, evidence-based decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailer Consolidation in Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJapan's drugstore and convenience-store sector is concentrated: in 2024 the top 10 drugstore chains held about 62% market share and the Big Three convenience chains (7‑Eleven, Lawson, FamilyMart) ran ~55% of urban outlets, giving them huge buying power over Kobayashi.\u003c\/p\u003e\n\u003cp\u003eThese retailers negotiate steep trade discounts—often 5–15% deeper than smaller buyers—and demand premium shelf placement and promotional funding, squeezing Kobayashi's gross margins by several hundred basis points on key OTC lines.\u003c\/p\u003e\n\u003cp\u003eOngoing consolidation—M\u0026amp;A and franchise rollups reduced independent pharmacy counts by ~12% from 2018–2023—means retailers can increasingly dictate pricing, payment terms, and product assortment to manufacturers like Kobayashi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFragile Brand Loyalty Post Recall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the 2024 safety recall that cut sales 18% in Q3 2024, customer trust is fragile and price-sensitive; surveys show 42% of past buyers say they will switch brands after one safety lapse, boosting buyer bargaining power. Retail returns rose 27% and net promoter score fell 14 points, so consumers now demand clearer transparency and safety guarantees or will migrate to competitors, increasing switching risk and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Hygiene Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumers treat many household and hygiene items as interchangeable, driving high price elasticity; Kobayashi faced this in 2024 when 52% of Japanese shoppers cited price as the top purchase driver for toiletries (Nikkei, 2024), so price hikes risk immediate share loss to private labels. Online price transparency—price comparison apps and e-commerce listings—means shoppers can find alternatives within minutes, keeping downward pressure on margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for End Users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLow switching costs in OTC drugs and hygiene mean consumers can try alternatives with no financial penalty, and global FMCG data shows private-label share rose to 20% in several markets by 2024, pressuring branded players like Kobayashi.\u003c\/p\u003e\n\u003cp\u003eThis ease forces Kobayashi to keep innovating and spend on marketing—Japan consumer goods ad spend was ¥2.3 trillion in 2024—since no long-term contracts exist, shoppers hold pricing and loyalty power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNear-zero trial cost for consumers\u003c\/li\u003e\n\u003cli\u003ePrivate-label share ≈20% (2024)\u003c\/li\u003e\n\u003cli\u003eJapan ad spend ¥2.3T (2024)\u003c\/li\u003e\n\u003cli\u003eNo long-term contracts → buyer advantage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Transparency and Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumers now research ingredients and clinical efficacy before buying; 72% of skincare buyers said efficacy data influences purchases in a 2024 Euromonitor survey, pushing firms to publish trials and biomarkers.\u003c\/p\u003e\n\u003cp\u003eCompanies must spend more on evidence-based marketing—median ad+R\u0026amp;D share rose to 18% of revenue for public cos in 2023—to answer buyer queries and reduce churn.\u003c\/p\u003e\n\u003cp\u003eWithout transparent data, brands face rapid customer loss: a 2022 McKinsey panel found 38% of consumers switched brands for better transparency within 6 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% of buyers value efficacy data (Euromonitor 2024)\u003c\/li\u003e\n\u003cli\u003eMedian ad+R\u0026amp;D = 18% revenue (public firms, 2023)\u003c\/li\u003e\n\u003cli\u003e38% switched for transparency within 6 months (McKinsey 2022)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail consolidation squeezes Kobayashi: deep discounts, placement fees cut margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail consolidation and dominant chains (top‑10 drugstores ~62% share; Big Three convenience ~55% urban outlets, 2024) give buyers strong leverage, forcing deep trade discounts (5–15%) and premium placement demands that shave several hundred bps from Kobayashi’s gross margins; low switching costs, 20% private‑label share (2024), and high price sensitivity (52% cite price for toiletries, Nikkei 2024) amplify pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑10 drugstore share\u003c\/td\u003e\n\u003ctd\u003e~62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Three convenience urban outlets\u003c\/td\u003e\n\u003ctd\u003e~55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade discount uplift vs small buyers\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate‑label share\u003c\/td\u003e\n\u003ctd\u003e~20% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eToiletries: price top driver\u003c\/td\u003e\n\u003ctd\u003e52% (Nikkei 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eKobayashi Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Kobayashi Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document is fully formatted and ready to use, including supplier power, buyer power, competitive rivalry, threat of substitutes, and barriers to entry assessments tailored to Kobayashi.\u003c\/p\u003e\n\u003cp\u003eOnce you buy, you’ll get instant access to this same comprehensive file for download and application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747252154745,"sku":"kobayashi-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kobayashi-five-forces-analysis.png?v=1772196628","url":"https:\/\/matrixbcg.com\/products\/kobayashi-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}